Jeremy V. Camp

Dr. Jeremy V. Camp

Center for Virology, Medical University of Vienna
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
JCJeremy V. Camp
Jeremy V. Camp
CJColleen Jonsson
Colleen Jonsson
Neutrophils are immune cells that are well-known to be present during many types of lung diseases associated with acute respiratory distress syndrome (ARDS), and may contribute to acute lung injury. Neutrophils are poorly studied with respect to viral infection, and specifically to respiratory viral disease. Influenza A virus (IAV) infection is the cause of a respiratory disease that poses a significant global public health concern. Influenza disease presents as a relatively mild and self-limiting although highly pathogenic forms exist. Neutrophils increase in the respiratory tract during infection with mild seasonal IAV, moderate and severe epidemic IAV infection, and emerging highly pathogenic avian influenza (HPAI). During severe influenza pneumonia (SIP) and HPAI infection, the number of neutrophils in the LRT is correlated with disease severity. Thus, comparative analyses of the relationship between IAV infection and neutrophils provide insights into the relative contribution of host and viral factors that contribute to disease severity. Herein, we review the contribution of neutrophils to IAV disease pathogenesis and to other respiratory virus infections.

9 September 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Nariman ShahhosseiniNariman Shahhosseini
Nariman Shahhosseini
GWGary Wong
Gary Wong
GBGEORGE BABUADZE
GEORGE BABUADZE
JCJeremy V. Camp
Jeremy V. Camp
Onder ErgonulOnder Ergonul
Onder Ergonul
Norbert NowotnyNorbert Nowotny
Norbert Nowotny
The global spread of ticks and various tick-borne viruses (TBVs) suggests the possibility of new tick-borne diseases emerging. Crimean-Congo hemorrhagic fever virus (CCHFV) is an emerging TBV of the Nairoviridae family that causes serious disease that can be fatal in humans. CCHFV endemic foci can be found in Africa, Asia, the Middle East, and South-Eastern Europe, and has spread to previously unaffected regions and nations, such as Spain, over the last two decades. In this review, we discuss the current situation of CCHFV in Asia, Africa and Europe based on existing knowledge, and we discuss driving factors in the distribution and transmission of the virus, such as the spread of tick vector species and host reservoirs.

14 January 2020 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
JCJeremy V. Camp
Jeremy V. Camp
Norbert NowotnyNorbert Nowotny
Norbert Nowotny
Introduction: West Nile virus (WNV) is a mosquito-borne human and animal pathogen with nearly world-wide distribution. In Europe, the virus is endemic with seasonal regional outbreaks that have increased in frequency over the last 10 years. A massive outbreak occurred across southern and central Europe in 2018 with the number of confirmed human cases increasing up to 7.2-fold from the previous year, and expanding to include previously virus-free regions. Areas covered: This review focuses on potential causes that may explain the 2018 European WNV outbreak. We discuss the role genetic, ecological, and environmental aspects may have played in the increased activity during the 2018 transmission season, summarizing the latest epidemiological and virological publications. Expert opinion: Optimal environmental conditions, specifically increased temperature, were most likely responsible for the observed outbreak. Other factors cannot be ruled out due to limited available information, including factors which may influence host/vector abundance and contact. Europe will likely experience even larger-scale outbreaks in coming years. Increased surveillance efforts should be implemented with a focus on early-warning detection methods, and large scale host and vector surveys should continue to fill gaps in knowledge.

6 December 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KSKaimei Song
Kaimei Song
DBDiane L. Bolton
Diane L. Bolton
CWChih-Jen Wei
Chih-Jen Wei
RWRobert L. Wilson
Robert L. Wilson
JCJeremy V. Camp
Jeremy V. Camp
SRSrinivas S. Rao
Srinivas S. Rao
Successful vaccination against respiratory infections requires elicitation of high levels of potent and durable humoral and cellular responses in the lower airways. To accomplish this goal, we used a fine aerosol that targets the entire lung surface through normal respiration to deliver replication-incompetent recombinant adenoviral vectors expressing gene products from several infectious pathogens. We show that this regimen induced remarkably high and stable lung T-cell responses in nonhuman primates and that it also generated systemic and respiratory tract humoral responses of both IgA and IgG isotypes. Moreover, strong immunogenicity was achieved even in animals with preexisting antiadenoviral immunity, overcoming a critical hurdle to the use of these vectors in humans, who commonly are immune to adenoviruses. The immunogenicity profile elicited with this regimen, which is distinct from either intramuscular or intranasal delivery, has highly desirable properties for protection against respiratory pathogens. We show that it can be used repeatedly to generate mucosal humoral, CD4, and CD8 T-cell responses and as such may be applicable to other mucosally transmitted pathogens such as HIV. Indeed, in a lethal challenge model, we show that aerosolized recombinant adenoviral immunization completely protects ferrets against H5N1 highly pathogenic avian influenza virus. Thus, genetic immunization in the lung offers a powerful platform approach to generating protective immune responses against respiratory pathogens.

14 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RGRachael L Gerlach
Rachael L Gerlach
JCJeremy V. Camp
Jeremy V. Camp
YCYong-Kyu Chu
Yong-Kyu Chu
CJColleen Jonsson
Colleen Jonsson
Replication, cell tropism and the magnitude of the host's antiviral immune response each contribute to the resulting pathogenicity of influenza A viruses (IAV) in humans. In contrast to seasonal IAV in human cases, the 2009 H1N1 pandemic IAV (H1N1pdm) shows a greater tropism for infection of the lung similar to H5N1. We hypothesized that host responses during infection of well-differentiated, primary human bronchial epithelial cells (wd-NHBE) may differ between seasonal (H1N1 A/BN/59/07) and H1N1pdm isolates from a fatal (A/KY/180/10) and nonfatal (A/KY/136/09) case. For each virus, the level of infectious virus and host response to infection (gene expression and apical/basal cytokine/chemokine profiles) were measured in wd-NHBE at 8, 24, 36, 48 and 72 hours post-infection (hpi). At 24 and 36 hpi, KY/180 showed a significant, ten-fold higher titer as compared to the other two isolates. Apical cytokine/chemokine levels of IL-6, IL-8 and GRO were similar in wd-NHBE cells infected by each of these viruses. At 24 and 36 hpi, NHBE cells had greater levels of pro-inflammatory cytokines including IFN-α, CCL2, TNF-α, and CCL5, when infected by pandemic viruses as compared with seasonal. Polarization of IL-6 in wd-NHBE cells was greatest at 36 hpi for all isolates. Differential polarized secretion was suggested for CCL5 across isolates. Despite differences in viral titer across isolates, no significant differences were observed in KY/180 and KY/136 gene expression intensity profiles. Microarray profiles of wd-NHBE cells diverged at 36 hpi with 1647 genes commonly shared by wd-NHBE cells infected by pandemic, but not seasonal isolates. Significant differences were observed in cytokine signaling, apoptosis, and cytoskeletal arrangement pathways. Our studies revealed differences in temporal dynamics and basal levels of cytokine/chemokine responses of wd-NHBE cells infected with each isolate; however, wd-NHBE cell gene intensity profiles were not significantly different between the two pandemic isolates suggesting post-transcriptional or later differences in viral-host interactions.

4 December 2020 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
CBChristoph Buchta
Christoph Buchta
IGIrene Görzer
Irene Görzer
PCPeter Chiba
Peter Chiba
JCJeremy V. Camp
Jeremy V. Camp
HHHeidemarie Holzmann
Heidemarie Holzmann
SAStephan W. Aberle
Stephan W. Aberle
Objectives: The qualitative results of SARS-CoV-2 specific real-time reverse transcription (RT) PCR are used for initial diagnosis and follow-up of Covid-19 patients and asymptomatic virus carriers. However, clinical decision-making and health management policies often are based additionally on cycle threshold (Ct) values (i.e., quantitative results) to guide patient care, segregation and discharge management of individuals testing positive. Therefore, an analysis of inter-protocol variability is needed to assess the comparability of the quantitative results. Methods: Ct values reported in a SARS-CoV-2 virus genome detection external quality assessment challenge were analyzed. Three positive and two negative samples were distributed to participating test laboratories. Qualitative results (positive/negative) and quantitative results (Ct values) were assessed. Results: A total of 66 laboratories participated, contributing results from 101 distinct test systems and reporting Ct values for a total of 92 different protocols. In all three positive samples, the means of the Ct values for the E-, N-, S-, RdRp-, and ORF1ab-genes varied by less than two cycles. However, 7.7% of reported results deviated by more than ±4.0 (maximum 18.0) cycles from the respective individual means. These larger deviations appear to be systematic errors. Conclusions: In an attempt to use PCR diagnostics beyond the identification of infected individuals, laboratories are frequently requested to report Ct values along with a qualitative result. This study highlights the limitations of interpreting Ct values from the various SARS-CoV genome detection protocols and suggests that standardization is necessary in the reporting of Ct values with respect to the target gene.